Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/43695
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHein, L.en
dc.contributor.authorMeikle, P.en
dc.contributor.authorHopwood, J.en
dc.contributor.authorFuller, M.en
dc.date.issued2007en
dc.identifier.citationMolecular Genetics and Metabolism, 2007; 92(4):336-345en
dc.identifier.issn1096-7192en
dc.identifier.issn1096-7206en
dc.identifier.urihttp://hdl.handle.net/2440/43695-
dc.descriptionCopyright © 2007 Elsevier Inc. All rights reserved.en
dc.description.abstractGlucosylceramide (GC) is a metabolic intermediate derived from the cellular turnover of membrane gangliosides and globosides. The catabolism of GC is impaired in Gaucher disease (GD) and consequently GC accumulates in affected cells leading to clinical manifestations of GD. The primary cell type affected in GD is the macrophage, and we investigated what effect excess GC has on the spatial coordination of other sphingolipids and phospholipids in a macrophage model of GD. A THP-1 macrophage model of GD was established by supplementation of the culture media with conduritol B epoxide, a specific irreversible inhibitor of acid beta-glucosidase. This cell model accumulated up to 12-fold more GC compared with untreated cells. Sub-cellular fractionation showed that, initially, the primary site of GC accumulation was the lysosome but as more GC accumulated it distributed relatively evenly across the cell and was present in all sub-cellular fractions. We also observed secondary elevations in the concentrations of ceramide, di- and trihexosylceramide and phosphatidylglycerol, which all had similar sub-cellular distributions to that of GC, initially increasing in the lysosome and then throughout the sub-cellular compartments. Our results suggest that with excess GC accumulation, the pathway trafficking GC to the lysosome becomes saturated and GC as well as other sphingolipids are shunted to other parts of the cell. The presence of these sphingolipids at non-physiological concentrations is likely to interfere with other biochemical pathways outside the lysosome, leading to cell dysfunction and ultimately pathological mechanisms apparent in GD, such as macrophage activation.en
dc.description.statementofresponsibilityLeanne K. Hein, Peter J. Meikle, John J. Hopwood and Maria Fulleren
dc.description.urihttp://www.elsevier.com/wps/find/journaldescription.cws_home/622920/description#descriptionen
dc.language.isoenen
dc.publisherAcademic Press Inc Elsevier Scienceen
dc.subjectCells, Cultured; Macrophages; Humans; Gaucher Disease; Glucosylceramides; Sphingolipids; Models, Biologicalen
dc.titleSecondary sphingolipid accumulation in a macrophage model of Gaucher diseaseen
dc.typeJournal articleen
dc.identifier.rmid0020074034en
dc.identifier.doi10.1016/j.ymgme.2007.08.001en
dc.identifier.pubid46617-
pubs.library.collectionPaediatrics publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
Appears in Collections:Paediatrics publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.